Roivant Sciences Ltd. ROIV
Institutional shares held
456 Million
8.36M
calls
760K
puts
Total value of holdings
$5.27B
$96.8M
calls
$8.79M
puts
Market Cap
$8.15B
704,382,976
Shares Out.
Institutional ownership
64.69%
# of Institutions
363
We take great care to ensure that the data presented and summarized in this overview for Roivant Sciences Ltd. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ROIV
View all-
Sb Investment Advisers (Uk) LTD London, X060MShares$694 Million5.36% of portfolio
-
Morgan Stanley New York, NY44.7MShares$517 Million0.03% of portfolio
-
Vanguard Group Inc Valley Forge, PA39.3MShares$455 Million0.01% of portfolio
-
Black Rock Inc. New York, NY35.4MShares$409 Million0.01% of portfolio
-
Viking Global Investors LP34.2MShares$396 Million1.22% of portfolio
-
Qvt Financial LP New York, NY29.4MShares$340 Million32.33% of portfolio
-
Rubric Capital Management LP New York, NY20.4MShares$236 Million5.29% of portfolio
-
State Street Corp Boston, MA19.8MShares$229 Million0.01% of portfolio
-
Patient Square Capital LP Menlo Park, CA12.5MShares$144 Million50.71% of portfolio
-
Two Seas Capital LP Rye, NY10.6MShares$123 Million2.22% of portfolio
Latest Institutional Activity in ROIV
Top Purchases
Top Sells
About ROIV
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.
Insider Transactions at ROIV
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 20
2025
|
Eric Venker President & Immunovant CEO |
SELL
Open market or private sale
|
Direct |
100,000
-5.7%
|
$1,100,000
$11.72 P/Share
|
|
Aug 20
2025
|
Eric Venker President & Immunovant CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
100,000
+5.4%
|
$300,000
$3.85 P/Share
|
|
Aug 20
2025
|
Eric Venker President & Immunovant CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
7,051
-0.42%
|
$77,561
$11.72 P/Share
|
|
Aug 20
2025
|
Richard Pulik CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,235
-0.31%
|
$13,585
$11.72 P/Share
|
|
Jul 30
2025
|
Eric Venker President & Immunovant CEO |
BUY
Grant, award, or other acquisition
|
Direct |
198,413
+10.67%
|
-
|
|
Jul 30
2025
|
Frank Torti President and Vant Chair |
BUY
Grant, award, or other acquisition
|
Direct |
13,736,547
+48.21%
|
-
|
|
Jul 28
2025
|
Richard Pulik CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,919
-0.48%
|
$21,109
$11.35 P/Share
|
|
Jul 21
2025
|
Eric Venker President & Immunovant CEO |
SELL
Open market or private sale
|
Direct |
100,000
-6.4%
|
$1,100,000
$11.52 P/Share
|
|
Jul 21
2025
|
Eric Venker President & Immunovant CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
100,000
+6.02%
|
$300,000
$3.85 P/Share
|
|
Jul 17
2025
|
Epperly Melissa B, |
BUY
Grant, award, or other acquisition
|
Direct |
1,609
+3.61%
|
-
|
|
Jul 17
2025
|
James C Momtazee |
SELL
Payment of exercise price or tax liability
|
Direct |
241
-0.25%
|
$2,651
$11.65 P/Share
|
|
Jul 17
2025
|
James C Momtazee |
BUY
Grant, award, or other acquisition
|
Direct |
1,201
+1.22%
|
-
|
|
Jun 28
2025
|
Richard Pulik CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,653
-0.41%
|
$18,183
$11.39 P/Share
|
|
Jun 25
2025
|
Qvt Financial LP |
SELL
Other acquisition or disposition
|
Indirect |
36,756,758
-66.47%
|
-
|
|
Jun 25
2025
|
Keith S Manchester |
SELL
Other acquisition or disposition
|
Indirect |
17,389,525
-49.71%
|
-
|
|
Jun 25
2025
|
Daniel Allen Gold |
SELL
Other acquisition or disposition
|
Indirect |
36,756,758
-66.47%
|
-
|
|
Jun 20
2025
|
Eric Venker President & Immunovant CEO |
SELL
Open market or private sale
|
Direct |
100,000
-6.4%
|
$1,100,000
$11.45 P/Share
|
|
Jun 20
2025
|
Eric Venker President & Immunovant CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
100,000
+6.02%
|
$300,000
$3.85 P/Share
|
|
Jun 20
2025
|
Richard Pulik CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,503
-0.38%
|
$16,533
$11.45 P/Share
|
|
Jun 20
2025
|
Vivek Ramaswamy > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
577,007
-1.52%
|
$6,347,077
$11.46 P/Share
|
Last 12 Months Summary
Buy / Acquisition
35.4M
Shares
From
15
Insiders
| Grant, award, or other acquisition | 14.3M shares |
|---|---|
| Exercise of conversion of derivative security | 7.77M shares |
| Bona fide gift | 13.4M shares |
Sell / Disposition
125M
Shares
From
25
Insiders
| Payment of exercise price or tax liability | 278K shares |
|---|---|
| Other acquisition or disposition | 95.1M shares |
| Open market or private sale | 15.9M shares |
| Bona fide gift | 13.4M shares |